On August 13, 2026, ClinicalTrials.gov listed an update for the study titled "Levothyroxine Supplementation for Heart Transplant Recipients," registered as NCT06428097. This trial involves vasopressin, an approved compound, and is currently in Phase 1. The trial status is listed as recruiting as of the noted date. No results have been posted for this trial according to the available record. The study record does not specify additional details such as enrollment numbers, sponsor, or specific endpoints beyond the title and phase provided. As this is a trial update rather than a results announcement, no efficacy or safety conclusions can be drawn from this listing. The recruiting status indicates the trial is actively seeking or continuing to enroll participants at this time. Interested readers can find further details, including eligibility criteria and study locations, through the official ClinicalTrials.gov listing. This update reflects only the administrative status of the trial as of the date given and does not represent findings or outcomes. For general background on vasopressin, its approved uses, and regulatory status, readers may consult the compound overview.</body_markdown>
<parameter name="sources">["https://clinicaltrials.gov/study/NCT06428097"]